VRTX
Vertex Pharmaceuticals
NASDAQ: VRTX · Boston, MA · Healthcare
$436.59-2.59 (-0.59%)Closed
Market Cap$112.00B
Cash$13.80Bmost recent
Runwayprofitable
P/E (TTM)29.5EPS $14.72
52-Wk Range$366.54 – $509.50
Avg Volume1.5M3-month
Healthstrong
Commercial-stage biotech with a dominant cystic fibrosis franchise, expanding into pain, T1D, and sickle cell via Casgevy.
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$436.59+9.2%
Pipeline
Drug candidates sponsored by Vertex Pharmaceuticals · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | LUM/IVA | Cystic Fibrosis | Completed | 2023-08-22past | 5 | |
| Phase 3 | Placebo | Cystic Fibrosis, Homozygous for the F508del CFTR Mutation+1 more | Completed | 2014-04past | 2 | |
| Phase 3 | VX-809 | Cystic Fibrosis | Completed | 2016-09past | 3 | |
| Phase 3 | VX-661/Ivacaftor | Cystic Fibrosis | Completed | 2017-02past | 1 | |
| Phase 3 | TEZ | Cystic Fibrosis | Completed | 2018-09past | 2 | |
| Phase 3 | VX-445/TEZ/IVA | Cystic Fibrosis | Completed | 2019-04-24past | 2 | |
| Phase 3 | VX-659/TEZ/IVA | Cystic Fibrosis | Completed | 2020-09-09past | 2 | |
| Phase 3 | Ivacaftor | Cystic Fibrosis | Completed | 2020-10past | 10 | |
| Phase 3 | TEZ/IVA | Cystic Fibrosis | Completed | 2020-10-28past | 2 | |
| Phase 3 | LUM | Cystic Fibrosis | Completed | 2021-10-29past | 1 | |
| Phase 3 | ELX/TEZ/IVA | Cystic Fibrosis | Completed | 2023-07-05past | 5 | |
| Phase 3 | IVA | Cystic Fibrosis | Completed | 2023-10-02past | 2 | |
| Phase 3 | SUZ | Acute Pain | Completed | 2023-12-15past | 1 | |
| Phase 3 | VX-121/TEZ/D-IVA | Cystic Fibrosis | Active, not recruiting | 2026-10-30 | 2 | |
| Phase 3 | Suzetrigine | Pain+1 more | Recruiting | 2027-05-31 | 3 | |
| Phase 2 | VX-147 | Proteinuric Kidney Disease+1 more | Recruiting | 2028-06-02 | 2 | |
| Phase 2 | CTX001 | Sickle Cell Disease+7 more | Completed | 2039-09-30 | 3 | |
| Phase 2 | biricodar dicitrate | Lung Cancer | Terminated | 2001-02past | 1 | |
| Phase 2 | Ivacaftor 25 mg/75 mg | Cystic Fibrosis | Completed | 2008-08past | 1 | |
| Phase 1 | Cethrin | Spinal Cord Injury | Completed | 2008-12past | 1 | |
| Phase 2 | VX-770 | Cystic Fibrosis+1 more | Completed | 2013-02past | 4 | |
| Phase 2 | VX-765 Part A | Epilepsy | Terminated | 2013-08past | 1 | |
| Phase 2 | Telaprevir | Hepatitis C | Completed | 2014-04past | 3 | |
| Phase 2 | VX-135 | Chronic Hepatitis C+3 more | Completed | 2014-05past | 1 | |
| Phase 2 | VX-509 | Rheumatoid Arthritis | Completed | 2014-07past | 2 | |
| Phase 2 | VX-561 | Cystic Fibrosis | Terminated | 2017-08past | 1 | |
| Phase 2 | Tezacaftor/Ivacaftor | Cystic Fibrosis | Completed | 2018-07past | 1 | |
| Phase 2 | VX-150 | Osteoarthritis+1 more | Completed | 2019-01-17past | 3 | |
| Phase 1 | Placebo (matched to VX-121 suspension) | Cystic Fibrosis | Completed | 2019-05-03past | 1 | |
| Phase 2 | VX-548 | Acute Pain+1 more | Completed | 2024-03-30past | 5 | |
| Phase 2 | VX-864 | Alpha1-Antitrypsin Deficiency+1 more | Completed | 2024-08-19past | 2 | |
| Phase 1 | VX-264 | Type 1 Diabetes | Active, not recruiting | 2026-05-29 | 1 | |
| Phase 1 | VX-522 mRNA therapy | Cystic Fibrosis | Recruiting | 2026-12-23 | 1 | |
| Phase 2 | Inaxaplin | Proteinuric Kidney Disease | Recruiting | 2026-12-30 | 1 | |
| Phase 2 | VX-670 | Myotonic Dystrophy Type 1 (DM1) | Enrolling | 2029-01-30 | 1 | |
| Phase 1 | VCH-759 (BCH-27759) | Hepatitis C, Chronic | Completed | — | 1 | |
| Phase 1 | VCH 916 | HCV Infection | Completed | 2008-10past | 1 | |
| Phase 1 | VX-985 or matching placebo | Chronic Hepatitis C | Completed | 2010-10past | 1 | |
| Phase 1 | lumacaftor 200 mg q12h + ivacaftor 250 mg q12h | Hepatic Impairment+1 more | Completed | 2013-11past | 1 | |
| Phase 1 | Lumacaftor | Cystic Fibrosis | Completed | 2014-03past | 2 | |
| Phase 1 | VX-440 | Cystic Fibrosis | Completed | 2016-09-14past | 1 | |
| Phase 1 | VX-840 | APOL1-mediated Kidney Disease | Completed | 2022-11-07past | 1 | |
| Phase 1 | VX-708 | Pain | Completed | 2023-03-07past | 1 | |
| Phase 1 | VX-634 | Alpha 1-Antitrypsin Deficiency | Completed | 2023-05-24past | 1 | |
| Phase 1 | VX-668 | Alpha-1 Antitrypsin Deficiency | Completed | 2023-09-12past | 1 | |
| Phase 1 | VX-993 | Pain | Completed | 2023-09-12past | 1 | |
| Phase 1 | VX-828 | Cystic Fibrosis | Completed | 2025-05-05past | 1 | |
| Phase 1 | 14C-VX-993 | Pain | Completed | 2025-05-17past | 1 | |
| Phase 1 | VX-407 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Completed | 2026-02-24past | 2 | |
| Phase 1 | VNZ/TEZ/D-IVA | Cystic Fibrosis | Completed | 2026-02-28past | 1 | |
| Phase 1 | VX-272 | Cystic Fibrosis | Recruiting | 2027-03-23 | 1 | |
| N/A | AVN944 | Refractory Solid Tumors | Withdrawn | 2010-03past | 1 | |
| N/A | Unnamed | Cystic Fibrosis | Completed | 2019-12past | 1 | |
| N/A | Unnamed | Cystic Fibrosis | Completed | 2021-12-20past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.